PL378561A1 - Polimorf {6,7-bis(2-metoksyetoksy) chinazolin-4-ylo}-(3e) - Google Patents

Polimorf {6,7-bis(2-metoksyetoksy) chinazolin-4-ylo}-(3e)

Info

Publication number
PL378561A1
PL378561A1 PL378561A PL37856104A PL378561A1 PL 378561 A1 PL378561 A1 PL 378561A1 PL 378561 A PL378561 A PL 378561A PL 37856104 A PL37856104 A PL 37856104A PL 378561 A1 PL378561 A1 PL 378561A1
Authority
PL
Poland
Prior art keywords
quinazolin
ethoxy
methoxy
bis
polymorph
Prior art date
Application number
PL378561A
Other languages
English (en)
Other versions
PL225428B1 (pl
Inventor
Andre Gerard Bubendorf
Michael Hennig
Pirmin Hidber
Goesta Rimmler
Franziska Rohrer
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32842701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL378561(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL378561A1 publication Critical patent/PL378561A1/pl
Publication of PL225428B1 publication Critical patent/PL225428B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL378561A 2003-02-17 2004-02-11 Sposób wytwarzania krystalicznego polimorfu chlorowodorku [6,7-bis(2-metoksyetoksy)chinazolin-4-ylo]-(3-etynylofenylo)aminy PL225428B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03003587.7 2003-02-17
EP03003587 2003-02-17
PCT/EP2004/001244 WO2004072049A1 (en) 2003-02-17 2004-02-11 Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)

Publications (2)

Publication Number Publication Date
PL378561A1 true PL378561A1 (pl) 2006-05-02
PL225428B1 PL225428B1 (pl) 2017-04-28

Family

ID=32842701

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378561A PL225428B1 (pl) 2003-02-17 2004-02-11 Sposób wytwarzania krystalicznego polimorfu chlorowodorku [6,7-bis(2-metoksyetoksy)chinazolin-4-ylo]-(3-etynylofenylo)aminy

Country Status (24)

Country Link
US (1) US7148231B2 (pl)
EP (1) EP1597239B2 (pl)
JP (1) JP4456079B2 (pl)
KR (1) KR100797430B1 (pl)
CN (1) CN100506803C (pl)
AT (1) ATE408605T1 (pl)
AU (1) AU2004212067C1 (pl)
BR (1) BRPI0407520A (pl)
CA (1) CA2514977C (pl)
CO (1) CO5601019A2 (pl)
DE (1) DE602004016628D1 (pl)
DK (1) DK1597239T4 (pl)
ES (1) ES2314373T5 (pl)
HR (1) HRP20050707B1 (pl)
IL (1) IL169975A (pl)
MX (1) MXPA05008598A (pl)
NO (1) NO330781B1 (pl)
NZ (1) NZ541500A (pl)
PL (1) PL225428B1 (pl)
PT (1) PT1597239E (pl)
RU (1) RU2376294C2 (pl)
SI (1) SI1597239T2 (pl)
WO (1) WO2004072049A1 (pl)
ZA (1) ZA200506339B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
PL2032521T3 (pl) 2006-06-27 2010-05-31 Sandoz Ag Nowy sposób wytwarzania soli
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
ES2573931T3 (es) * 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
JP5524041B2 (ja) * 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
EP2218713A1 (en) 2007-08-17 2010-08-18 Hetero Drugs Limited Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
TW200925152A (en) * 2007-08-23 2009-06-16 Plus Chemicals S A Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
EP2213281A1 (en) 2009-02-02 2010-08-04 Ratiopharm GmbH Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
CN101987834B (zh) * 2010-06-13 2012-07-18 信泰制药（苏州）有限公司 一种结晶形态的盐酸埃罗替尼及其制备方法
CA2806273A1 (en) 2010-07-23 2012-03-08 Generics (Uk) Limited Pure erlotinib
WO2012150606A2 (en) 2011-05-03 2012-11-08 Cadila Healthcare Limited A process for preparing stable polymophic form of erlotinib hydrochloride
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
RU2610337C1 (ru) * 2015-12-10 2017-02-09 Индивидуальный предприниматель Михайлов Олег Ростиславович Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) * 2017-09-26 2019-04-18 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) * 2018-12-05 2020-06-11 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6434574A (en) * 1987-07-30 1989-02-06 Mazda Motor Full mold casting device
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
US5747498A (en) † 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TR200003166T2 (tr) 1998-04-29 2001-02-21 Osi Pharmaceuticals, Inc. N-(3-etinilfenilamino)-6, 7-bis(2-metoksietoksi)-4-kuinozolamin mesilat anhidrat ve monohidrat.
RS49836B (sr) * 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування

Also Published As

Publication number Publication date
NO20053953L (no) 2005-08-31
PL225428B1 (pl) 2017-04-28
JP2006521288A (ja) 2006-09-21
DK1597239T3 (da) 2008-12-08
NZ541500A (en) 2008-03-28
WO2004072049A1 (en) 2004-08-26
EP1597239B2 (en) 2022-07-20
DK1597239T4 (da) 2022-09-26
CA2514977A1 (en) 2004-08-26
US7148231B2 (en) 2006-12-12
BRPI0407520A (pt) 2006-02-14
KR100797430B1 (ko) 2008-01-23
ES2314373T3 (es) 2009-03-16
AU2004212067B2 (en) 2009-03-19
HRP20050707B1 (hr) 2013-10-25
US20040162300A1 (en) 2004-08-19
ES2314373T5 (es) 2022-10-11
NO330781B1 (no) 2011-07-18
CN1751032A (zh) 2006-03-22
PT1597239E (pt) 2008-10-10
KR20050095898A (ko) 2005-10-04
CN100506803C (zh) 2009-07-01
SI1597239T1 (sl) 2009-02-28
HRP20050707A2 (en) 2006-07-31
ATE408605T1 (de) 2008-10-15
MXPA05008598A (es) 2005-11-04
DE602004016628D1 (de) 2008-10-30
ZA200506339B (en) 2006-05-31
CO5601019A2 (es) 2006-01-31
JP4456079B2 (ja) 2010-04-28
EP1597239B1 (en) 2008-09-17
IL169975A (en) 2011-06-30
SI1597239T2 (sl) 2022-10-28
EP1597239A1 (en) 2005-11-23
RU2376294C2 (ru) 2009-12-20
AU2004212067C1 (en) 2009-09-24
CA2514977C (en) 2010-06-22
RU2005128774A (ru) 2006-05-10
AU2004212067A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
PL378561A1 (pl) Polimorf {6,7-bis(2-metoksyetoksy) chinazolin-4-ylo}-(3e)
AP1434A (en) Stable polymorph of N-(3-Ethynylphenylamino) -6, 7-bis (2-methoxyethoxy) -4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof.
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
UA84167C2 (ru) Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
YU84603A (sh) Novi inhibitori tirozin kinaze
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
MY138851A (en) Quinazoline derivatives
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer
MXPA04005151A (es) Compuestos terapeuticos.
WO2005097755A3 (de) Imidazolderivate als hemmer von tyrosinkinase
MXPA04000037A (es) Isoxasolil-pirimidinas como inhibidores de proteinas cinasas src y lck.